Biotest Pharmaceuticals Corporation Revenue and Competitors

Miami, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Biotest Pharmaceuticals Corporation's estimated annual revenue is currently $282.6M per year.(i)
  • Biotest Pharmaceuticals Corporation's estimated revenue per employee is $201,000

Employee Data

  • Biotest Pharmaceuticals Corporation has 1406 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.5M132N/AN/AN/A
#2
$7.2M3624%N/AN/A
#3
$282.6M1406N/AN/AN/A
#4
$9.6M4833%N/AN/A
#5
$10.9M54-7%N/AN/A
#6
$12.3M61-5%N/AN/A
#7
$211.7M854-2%N/AN/A
#8
$22.9M11418%N/AN/A
#9
$8M4014%N/AN/A
#10
$13.1M6516%N/AN/A
Add Company

Biotest Pharmaceuticals researches and manufactures biotherapeutic products with a specialization in immunology and liver transplant therapy. Biotest Pharmaceuticals is a leader in the collection of plasma proteins and is currently involved in the development of products in the field of Primary Immune Deficiency (PID) and development of therapies for liver transplantation. Biotest Pharmaceuticals was formed in 2007 as part of the acquisition of Nabi Biopharmaceuticals’ Biologics business unit which includes its plasmapheresis centers across the United States by Biotest AG. We employ approximately 500 people in the US. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins therapies and diagnostics that employs approximately 1,750 people worldwide.

keywords:N/A

N/A

Total Funding

1406

Number of Employees

$282.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biotest Pharmaceuticals Corporation News

2022-04-20 - Fraccionamiento de plasma Mercado Comparta, informe y ...

Bio Product Laboratory Ltd. LFB S.A.. Biotest Pharmaceuticals Corporation Japan Blood Products Organization China Biologic Products Holdings,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$472.3M14867%N/A
#2
$657.3M173924%N/A
#3
$2250M18257%$105M
#4
$652.9M1836N/AN/A
#5
$724.6M1917-1%N/A